Top

Published in:

01-09-2014

Novel drugs targeting the androgen receptor pathway in prostate cancer

Authors: Joaquin Mateo, Alan Smith, Michael Ong, Johann S. de Bono

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Abstract

After decades of limited success in the treatment of castration-resistant prostate cancer (CRPC), five novel therapeutics were granted Food and Drug Administration regulatory approval in the last 4 years based on several randomized phase III studies that have reported a survival benefit. Among them, two drugs targeting the androgen receptor pathway, namely abiraterone acetate and enzalutamide, have demonstrated that targeting androgen signalling following progression to classical androgen blockade continues to be an effective strategy despite the emergence of resistance mechanisms to sequential treatments. In addition to these two approved drugs, several other promising agents that block steroidogenesis interact with the androgen receptor or modulate post-receptor signal transduction that are undergoing clinical evaluation. This issue reviews the current data and the state of development of novel androgen receptor-targeting drugs and further discusses how this revolution in therapeutic armamentarium for the treatment of CRPC has raised challenges for clinicians about the optimal usage of these compounds.

White W. (1893). Surgical removal of the hypertrophied prostate. Annals of Surgery, 18, 152–158.

Adams, J. (1853). The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet, 1, 393.

Huggins, C., & Hodges, C. (1941). The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prosta. Cancer Research, 1, 293–297.

Sandow, J., Von Rechenberg, W., Jerzabek, G., & Stoll, W. (1978). Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertility and Sterility, 30, 205–209.PubMed

The Leuprolide Study Group. (1984). Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. New England Journal of Medicine, 311, 1281–1286.CrossRef

Mainwaring, W. I. (1969). A soluble androgen receptor in the cytoplasm of rat prostate. Journal of Endocrinology, 45, 531–541.PubMedCrossRef

Anderson, K. M., & Liao, S. (1968). Selective retention of dihydrotestosterone by prostatic nuclei. Nature, 219, 277–279. 20.PubMedCrossRef

Bruchovsky, N., & Wilson, J. D. (1968). The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. Journal of Biological Chemistry, 243, 5953–5960. 25.PubMed

Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., et al. (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine, 321, 419–424. 17.PubMedCrossRef

10.

Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., et al. (1996). A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer, 78, 2164–2169. 15.PubMedCrossRef

11.

Pienta, K. J., & Bradley, D. (2006). Mechanisms nnderlying the development of androgen-independent prostate cancer. Clinical Cancer Research, 12, 1665–1671. 15.PubMedCrossRef

12.

De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364, 1995–2005. 26.PubMedCentralPubMedCrossRef

13.

Ryan, C. J., Smith, M. R., De Bono, J. S., Molina, A., Logothetis, C. J., De Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368, 138–148. 10.PubMedCentralPubMedCrossRef

14.

Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187–1197. 27.PubMedCrossRef

15.

Cunha, G. R., Ricke, W., Thomson, A., Marker, P. C., Risbridger, G., Hayward, S. W., et al. (2004). Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology, 92, 221–236.PubMedCrossRef

16.

Auchus, M. L., & Auchus, R. J. (2012). Human steroid biosynthesis for the oncologist. Journal of Investigative Medicine, 60, 495–503.PubMedCentralPubMed

17.

Sharifi, N., & Auchus, R. J. (2012). Steroid biosynthesis and prostate cancer. Steroids, 77, 719–726.PubMedCrossRef

18.

Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews, 32, 81–151.PubMedCentralPubMedCrossRef

19.

Brinkmann, A. O., Klaasen, P., Kuiper, G. G., Van der Korput, J. A., Bolt, J., De Boer, W., et al. (1989). Structure and function of the androgen receptor. Urological Research, 17, 87–93.PubMedCrossRef

20.

Klokk, T. I., Kurys, P., Elbi, C., Nagaich, A. K., Hendarwanto, A., Slagsvold, T., et al. (2007). Ligand-specific dynamics of the androgen receptor at its response element in living cells. Molecular and Cellular Biology, 27, 1823–1843.PubMedCentralPubMedCrossRef

21.

Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine, 332, 1393–1398.PubMedCrossRef

22.

Pratt, W. B., & Toft, D. O. (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews, 18, 306–360.PubMed

23.

Velasco, A. M., Gillis, K. A., Li, Y., Brown, E. L., Sadler, T. M., Achilleos, M., et al. (2004). Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology, 145, 3913–3924.PubMedCrossRef

24.

Agoulnik, I. U., & Weigel, N. L. (2009). Coactivator selective regulation of androgen receptor activity. Steroids, 74, 669–674.PubMedCentralPubMedCrossRef

25.

Attard, G., Belldegrun, A. S., & De Bono, J. S. (2005). Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International, 96, 1241–1246.PubMedCrossRef

26.

Brendler, H. (1973). Adrenalectomy and hypophysectomy for prostatic cancer. Urology, 2, 99–102.PubMedCrossRef

27.

Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. a., Penning, T. M., et al. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research, 66, 2815–2825.PubMedCrossRef

28.

Montgomery, R. B., Mostaghel, E. a., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68, 4447–4454.PubMedCentralPubMedCrossRef

29.

Isaacs, J. T., & Coffey, D. S. (1981). Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Research, 41, 5070–5075.PubMed

30.

Page, S. T., Lin, D. W., Mostaghel, E. a., Hess, D. L., True, L. D., Amory, J. K., et al. (2006). Persistent intraprostatic androgen concentrations after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism, 91, 3850–3856.PubMedCrossRef

31.

Donovan, M. J., Osman, I., Khan, F. M., Vengrenyuk, Y., Capodieci, P., Koscuiszka, M., et al. (2010). Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU International, 105, 462–467.PubMedCrossRef

32.

Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., et al. (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Research, 59, 803–806. 15.PubMed

33.

Watson, P. a., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., et al. (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 107, 16759–16765. 28.PubMedCentralPubMedCrossRef

34.

Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research, 68, 5469–5477.PubMedCentralPubMedCrossRef

35.

Waltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., et al. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research, 69, 8141–8149. 15.PubMedCrossRef

36.

Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. a., Picus, J., et al. (2003). Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. Journal of Clinical Oncology, 21, 2673–2678. 15.PubMedCrossRef

37.

Matias, P. M., Carrondo, M. A., Coelho, R., Thomaz, M., Zhao, X.-Y., Wegg, A., et al. (2002). Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. Journal of Medicinal Chemistry, 45, 1439–1446. 28.PubMedCrossRef

38.

Miller, W. L., Auchus, R. J., & Geller, D. H. (1997). The regulation of 17,20 lyase activity. Steroids, 62, 133–142.PubMedCrossRef

39.

Attard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., et al. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. Journal of Clinical Endocrinology and Metabolism, 97, 507–516.PubMedCrossRef

40.

Pont, A., Williams, P. L., Azhar, S., Reitz, R. E., Bochra, C., Smith, E. R., et al. (1982). Ketoconazole blocks testosterone synthesis. Archives of Internal Medicine, 142, 2137–2140.PubMedCrossRef

41.

Haidar, S., Ehmer, P. B., Barassin, S., Batzl-Hartmann, C., & Hartmann, R. W. (2003). Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. Journal of Steroid Biochemistry and Molecular Biology, 84, 555–562.PubMedCrossRef

42.

Reid, A. H., Attard, G., Barrie, E., & De Bono, J. S. (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nature Clinical Practice Urology, 5, 610–620.PubMedCrossRef

43.

Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994). Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). Journal of Steroid Biochemistry and Molecular Biology, 50, 267–273.PubMedCrossRef

44.

Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995). Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry, 38, 2463–2471. 23.PubMedCrossRef

45.

Attard, G., Reid, A. H. M., A’Hern, R., Parker, C., Oommen, N. B., Folkerd, E., et al. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology, 27, 3742–3748. 10.PubMedCentralPubMedCrossRef

46.

O’Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., et al. (2004). Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer, 90, 2317–2325. 14.PubMedCentralPubMed

47.

Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., et al. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of Clinical Oncology, 28, 1489–1495. 20.PubMedCentralPubMedCrossRef

48.

Luthy, I. A., Begin, D. J., & Labrie, F. (1988). Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. Journal of Steroid Biochemistry, 31, 845–852.PubMedCrossRef

49.

Attard, G., Cooper, C. S., & De Bono, J. S. (2009). Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell, 16, 458–462. 8.PubMedCrossRef

50.

Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., et al. (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology, 28, 1481–1488. 20.PubMedCentralPubMedCrossRef

51.

Danila, D. C., Morris, M. J., De Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., et al. (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 1496–1501. 20.PubMedCentralPubMedCrossRef

52.

Logothetis, C. J., Basch, E., Molina, A., Fizazi, K., North, S. A., Chi, K. N., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13, 1210–1217.PubMedCrossRef

53.

Matsunaga, N., Kaku, T., Ojida, A., Tanaka, T., Hara, T., Yamaoka, M., et al. (2004). C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorganic & Medicinal Chemistry, 12, 4313–4336.CrossRef

54.

Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., et al. (2012). Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. The Journal of Steroid Biochemistry and Molecular Biology, 129, 115–128.PubMedCrossRef

55.

Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., et al. (2013). Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. The Journal of Steroid Biochemistry and Molecular Biology, 134, 80–91.PubMedCrossRef

56.

Dreicer, R., Agus, D. B. , Bellmunt, J., De Bono, J.S., Petrylak, D., Tejura, B., et al. (2012). A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based chemotherapy [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr TPS4693).

57.

Agus, D. B., Stadler, W. M., Shevrin, D. H., Hart, L., Macvicar, G. R., Hainsworth, J. D., et al. (2012). Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. [abstract]. Journal of Clinical Oncology, 50, 50–51. 30, 2012 (suppl 5; abstr 98).

58.

Handratta, V. D., Vasaitis, T. S., Njar, V. C. O., Gediya, L. K., Kataria, R., Chopra, P., et al. (2005). Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry, 48, 2972–2984. 21.PubMedCrossRef

59.

Vasaitis, T., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., et al. (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics, 7, 2348–2357.PubMedCentralPubMedCrossRef

60.

DeVore, N. M., & Scott, E. E. (2012). Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature, 482(7383), 116–119.PubMedCentralPubMedCrossRef

61.

Bruno, R., Lu, J.-F., Sun, Y.-N., & Claret, L. (2011). A modeling and simulation framework to support early clinical drug development decisions in oncology. Journal of Clinical Pharmacology, 51, 6–8.PubMedCrossRef

62.

Schayowitz, A., Sabnis, G., Njar, V. C. O., & Brodie, A. M. H. (2008). Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics, 7, 121–132.PubMedCrossRef

63.

Montgomery, R. B., Eisenberger, M. a., Rettig, M., Chu, F., Pili, R., Stephenson, J., et al. (2012). Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4665). 2012.

64.

Eisner, J. R., Aboott, D., I.M. B, Rafferty, S. W., Schotzinger, R. J. (2012). Assessment of Steroid Hormones Upstream of P450c17 (CYP17) in Chemically Castrate Male Rhesus Monkeys Following Treatment with the CYP17 Inhibitors VT‐464 and Abiraterone Acetate (AA) [abstract]. Endocrine Reviews, 2012; Vol 33 (03_MeetingAbstracts): Sat 266.

65.

Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Wongvipat, J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787–790.PubMedCentralPubMedCrossRef

66.

Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. a., et al. (2013). Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife, 2, e00499.PubMedCentralPubMedCrossRef

67.

Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., et al. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet, 375, 1437–1446.PubMedCentralPubMedCrossRef

68.

Treiman, D. M. (2001). GABAergic mechanisms in epilepsy. Epilepsia, 42(Suppl 3), 8–12.PubMedCrossRef

69.

Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., et al. (2012). ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research, 72, 1494–1503.PubMedCentralPubMedCrossRef

70.

Rathkopf, D. E., Morris, M. J., Danila, D. C., Slovin, S., Steinbrecher, J., Arauz, G., et al. (2012). A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4548). 2012.

71.

Smith, M., Antonarakis, E. S., Ryan, C. J., Berry, W., Shore, N., Liu, G., et al. (2012) Arn-509 in men with high risk non-metastatic castration-resistant prostate cancer [abstract]. Annals of Oncology, 23 (suppl 9) abst 920.

72.

Rathkopf, D. E., Antonarakis, E. S., Shore, N., Tutrone, R., Amlukai, J., Ryan, C. J., et al. (2012). Arn-509 in men with metastatic castration-resistant prostate cancer (CRPC) [abstract]. Annals of Oncology, 23 (suppl 9) abst 964.

73.

Bradbury, R. H., Acton, D. G., Broadbent, N. L., Brooks, a. N., Carr, G. R., Hatter, G., et al. (2013). Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorganic & Medicinal Chemistry Letters, 23, 1945–1948.CrossRef

74.

Loddick, S. a., Bradbury, R., Broadbent, N., Campbell, H., Gaughan, L., Growcott, J., et al. (2012). Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer [abstract]. Cancer Research, 72, 3848–3848.CrossRef

75.

Omlin, A., Jones, R. J., vn der Noll, R., Graham, J., Ong, M., Schellens, J. H. M., et al. (2013). A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC) [abstract]. Journal of Clinical Oncology, 31, 2013 (suppl; abstr 4511).

76.

Massard, C., James, N., Culine, S., Jones, R., Vuorela, A., Mustonen, M., et al. (2012). ARADES trial: a first- in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]. Annals of Oncology, 23 (suppl 9) abst LBA25.

77.

Attar, R. M., Jure-Kunkel, M., Balog, A., Cvijic, M. E., Dell-John, J., Rizzo, C. A., et al. (2009). Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Research, 69, 6522–6530.PubMedCrossRef

78.

Rathkopf, D., Liu, G., Carducci, M. A., Eisenberger, M. A., Anand, A., Morris, M. J., et al. (2011). Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research, 17, 880–887.PubMedCentralPubMedCrossRef

79.

Georget, V., Térouanne, B., Nicolas, J.-C., & Sultan, C. (2002). Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry, 41, 11824–11831.PubMedCrossRef

80.

Prescott, J., & Coetzee, G. A. (2006). Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Letters, 231, 12–19.PubMedCrossRef

81.

Saporita, A. J., Ai, J., & Wang, Z. (2007). The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate, 67, 509–520.PubMedCentralPubMedCrossRef

82.

Tsui, K.-H., Feng, T.-H., Lin, C.-M., Chang, P.-L., & Juang, H.-H. (2008). Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. Journal of Andrology, 29, 661–668.PubMedCrossRef

83.

Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bubley, G., et al. (2011). Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology, 78, 626–630.PubMedCentralPubMedCrossRef

84.

Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research, 67, 10455–10465.PubMedCrossRef

85.

Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R. L., Nelson, C., et al. (2005). Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research, 65, 11083–11093.PubMedCrossRef

86.

Andrieu, C., Taieb, D., Baylot, V., Ettinger, S., Soubeyran, P., De-Thonel, A., et al. (2010). Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene, 29, 1883–1896.PubMedCrossRef

87.

Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., et al. (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research, 73, 3109–3119.PubMedCrossRef

88.

Chi, K. N., Hotte, S. J., Ellard, S. L., Gingerich, J., Joshua, A., Yu, E. Y., et al. (2012). A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4514). 2012.

89.

Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I., et al. (2010). Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 4247–4254.PubMedCrossRef

90.

Chi, K. N., Siu, L. L., Hirte, H., Hotte, S. J., Knox, J., Kollmansberger, C., et al. (2008). A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research, 14, 833–839.PubMedCrossRef

91.

Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., et al. (2011). Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research, 71, 6019–6029.PubMedCentralPubMedCrossRef

92.

Cook, P. D. (1999). Making drugs out of oligonucleotides: a brief review and perspective. Nucleosides & Nucleotides, 18, 1141–1162.CrossRef

93.

Gleave, M. E., & Monia, B. P. (2005). Antisense therapy for cancer. Nature Reviews Cancer, 5, 468–479.PubMedCrossRef

94.

Zhang, Y., Castaneda, S., Dumble, M., Wang, M., Mileski, M., Qu, Z., et al. (2011). Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Molecular Cancer Therapeutics, 10, 2309–2319.PubMedCrossRef

95.

Bianchini, D., Omlin, A., Pezaro, C., Mukherji, D., Lorente Estelles. D., Zivi, A., et al. (2013). First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC) [abstract]. Journal of Clinical Oncology, 31 (suppl; abstr 5052).

96.

Richards, J., Lim, A. C., Hay, C. W., Taylor, A. E., Wingate, A., Nowakowska, K., et al. (2012). Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Research, 72, 2176–2182.PubMedCrossRef

97.

Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., et al. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology, 24(7), 1807–1812.PubMedCrossRef

98.

Noonan, K. L., North, S., Bitting, R. L., Armstrong, a. J., Ellard, S. L., & Chi, K. N. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology, 24(7), 1802–1807.PubMedCrossRef

99.

Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell, 129, 1261–1274.PubMedCentralPubMedCrossRef

100.

Mediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., et al. (2013). The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate, 73, 267–277.PubMedCentralPubMedCrossRef

101.

Trotta, A. P., Need, E. F., Selth, L. A., Chopra, S., Pinnock, C. B., Leach, D. A., et al. (2013). Knockdown of the co-chaperone SGTA results in the suppression of androgen and PI3K/AKT signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812–2823.

102.

Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., et al. (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer, 97, 678–685.PubMedCentralPubMedCrossRef

103.

Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. (2006). Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Research, 66, 7929–7933.PubMedCrossRef

104.

Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., et al. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 19, 575–586.PubMedCentralPubMedCrossRef

105.

Mostaghel, E. a., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., et al. (2007). Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research, 67, 5033–5041.PubMedCrossRef

106.

Smith, M., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., et al. (2013). Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). [abstract]. Journal of Clinical Oncology, 31, 2013 (suppl; abstr 5001).

107.

Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., Mason, M. D. (2006). Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Systematic Reviews. doi: 10.1002/14651858.CD006019.pub2

108.

Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., et al. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31. International Journal of Radiation Oncology Biology and Physics, 61, 1285–1290.CrossRef

109.

Bolla, M., De Reijke, T. M., Van Tienhoven, G., Oddens, J., Poortmans, P. M. P., Gez, E., et al. (2009). Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine, 360, 2516–2527.PubMedCrossRef

110.

McGuire, S. E., Lee, A. K., Cerne, J. Z., Munsell, M. F., Levy, L. B., Kudchadker, R. J., et al. (2013). PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. International Journal of Radiation Oncology Biology and Physics, 85, e39–e46.CrossRef

111.

Taplin, M.-E., Montgomery, R. B., Logothetis, C. J., Bubley, G. J., Richie, J. P., Dalkin, B. L., et al. (2012). Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. [abstract]. Journal of Clinical Oncology, 30, 2012 (suppl; abstr 4521).

Title: Novel drugs targeting the androgen receptor pathway in prostate cancer
Authors: Joaquin Mateo
Alan Smith
Michael Ong
Johann S. de Bono
Publication date: 01-09-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9472-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2014

Preface

Clinical models and biochemical predictors of VTE in lung cancer

Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel

Antibody-based imaging strategies for cancer

Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer